Literature DB >> 4856023

[Electron microscopy, cytological, and serological studies on the effect of endoxan on the primary and secondary response of the mouse to sheep erythrocytes].

F Gudat, B Keller, R Faes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4856023

Source DB:  PubMed          Journal:  Schweiz Med Wochenschr        ISSN： 0036-7672


× No keyword cloud information.
  25 in total

1.  Comprehensive landscape of immune-checkpoints uncovered in clear cell renal cell carcinoma reveals new and emerging therapeutic targets.

Authors:  Mathilde Sautreuil; Mahmoud Bentriou; Diana Tronik-Le Roux; Jérôme Vérine; Maria Belén Palma; Marina Daouya; Fatiha Bouhidel; Sarah Lemler; Joel LeMaoult; François Desgrandchamps; Paul-Henry Cournède; Edgardo D Carosella
Journal:  Cancer Immunol Immunother       Date:  2020-03-12       Impact factor: 6.968

Review 2.  An unexpected turn of fortune: targeting TRAIL-Rs in KRAS-driven cancer.

Authors:  Silvia von Karstedt; Henning Walczak
Journal:  Cell Death Discov       Date:  2020-03-17

3.  Tumor immune microenvironment in brain metastases from gynecologic malignancies.

Authors:  Corey M Gill; Megan R D'Andrea; Shannon Tomita; Jessa Suhner; Melissa Umphlett; Konstantin Zakashansky; Stephanie V Blank; Nadejda Tsankova; Raj K Shrivastava; Mary Fowkes; Valentin Kolev
Journal:  Cancer Immunol Immunother       Date:  2021-03-13       Impact factor: 6.968

4.  Predictive Value of CD8 Expression and FoxP3 Methylation in Nasopharyngeal Carcinoma Patients Treated with Chemoradiotherapy in a Non-endemic Area.

Authors:  E Muraro; E Vaccher; C Furlan; E Fratta; G Fanetti; D A Fae'; D Martorelli; M Cangemi; J Polesel; F Navarria; C Gobitti; E Comaro; C Scaini; C Pratesi; S Zanussi; V Lupato; G Grando; V Giacomarra; S Sulfaro; L Barzan; R Dolcetti; A Steffan; V Canzonieri; G Franchin
Journal:  Pathol Oncol Res       Date:  2020-06-21       Impact factor: 3.201

5.  Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience.

Authors:  Susan Chi; Kee Kiat Yeo; Chantel Cacciotti; Jungwhan Choi; Sanda Alexandrescu; Mary Ann Zimmerman; Tabitha M Cooney; Christine Chordas; Jessica Clymer
Journal:  J Neurooncol       Date:  2020-07-05       Impact factor: 4.130

6.  Predictive potential and need for standardization of PD-L1 immunohistochemistry.

Authors:  Spasenija Savic Prince; Lukas Bubendorf
Journal:  Virchows Arch       Date:  2018-09-01       Impact factor: 4.064

Review 7.  Harnessing cancer immunotherapy during the unexploited immediate perioperative period.

Authors:  Pini Matzner; Elad Sandbank; Elad Neeman; Oded Zmora; Vijaya Gottumukkala; Shamgar Ben-Eliyahu
Journal:  Nat Rev Clin Oncol       Date:  2020-02-17       Impact factor: 66.675

Review 8.  Combination immunotherapy strategies for glioblastoma.

Authors:  Hok Yee Chan; John Choi; Christina Jackson; Michael Lim
Journal:  J Neurooncol       Date:  2021-02-21       Impact factor: 4.130

Review 9.  Intersection of FcγRIIB, the microbiome, and checkpoint inhibitors in antitumor immunity.

Authors:  Kirsten M Baecher; Mandy L Ford
Journal:  Cancer Immunol Immunother       Date:  2021-07-09       Impact factor: 6.968

Review 10.  Current status and future perspectives of immunotherapy in bladder cancer treatment.

Authors:  Zhangsong Wu; Jinjian Liu; Ruixiang Dai; Song Wu
Journal:  Sci China Life Sci       Date:  2020-08-26       Impact factor: 6.038
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.